Drug Pipeline
| Stage | Drug Name | AKA | LAB | |
| Pre-clinical | Glial Growth Factor 2 | GGF2 | Acorda | |
| Pre-clinical | AEG35156 | XIAP antagonist | Aegera | |
| Pre-clinical | NAPVSIPQ | NAP | Allon | |
| Pre-clinical | AT-008 | Androclus | ||
| Pre-clinical | CD83 | Argos Therapeutics | ||
| Pre-clinical | AZD 8797 | AstraZeneca | ||
| Pre-clinical | ESPRIT | Exon Skipping Pre-RNA Interference | AVI BioPharma | |
| Pre-clinical | CF101 | Can Fite BioPharma | ||
| Pre-clinical | CF402 | Can Fite BioPharma | ||
| Pre-clinical | Neurodur | CepTor | ||
| Pre-clinical | Nicotinamide | a form of vitamin B3 | Children’s Hospital – Boston | |
| Pre-clinical | LLDT-8 | Chinese Academy of Sciences | ||
| Pre-clinical | Interferon-beta – electroporation | EP-mediated intramuscul ar IFN-beta gene transfer | Cleveland Clinic | |
| Pre-clinical | CGEN-54 | Compugen | ||
| Pre-clinical | Peptidomimetics of apoE protein | apolipoprotein, COG133 | D uke University | |
| Pre-clinical | Neutrazumab | C5a Receptor antagonist | G2 Therapies | |
| Pre-clinical | GEMS-001 | Gemacbio | ||
| Pre-clinical | CD3 antibodies | Harvard | ||
| Pre-clinical | HE3204 | Hollis-Eden | ||
| Pre-clinical | Vitamin B12 | Hospital for Sick Children – Toronto | ||
| Pre-clinical | Epratuzumab | IMMU-103 | Immunomedics | |
| Pre-clinical | Bowmann-Birk Inhibitor Concentrate | BBIC | Jefferson Medical College | |
| Pre-clinical | CEP-701 | Johns Hopkins | ||
| Pre-clinical | 13-cis-retinoic acid | Kinemed | ||
| Pre-clinical | Fasudil | Kyushu University | ||
| Pre-clinical | LJP 1207 | La Jolla Pharmaceuticals | ||
| Pre-clinical | hBCMA-Fc | La Trobe University – Australia | ||
| Pre-clinical | LX2931 | Lexicon Genetics | ||
| Pre-clinical | Calpeptin | calpain-specific inhibitor | Medical U of S Carol ina | |
| Pre-clinical | sTNFR:Fc/p80 | Medical University of Lodz, Poland | ||
| Pre-clinical | 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside | AIC AR | Medical University of South Carolina | |
| Pre-clinical | Cathepsin S | Medivir | ||
| Pre-clinical | MT203 | human anti-GM-CSF IgG1 antibody | Micromet AG | |
| Pre-clinical | Mikbeta1 | National Institutes of Health | ||
| Pre-clinical | OPN-101 | Opsona | ||
| Pre-clinical | BVA-101 | Biovista | ||
| Pre-clinical | DP IV and APN inhibition | Otto-von-Guericke University, Ger many | ||
| Pre-clinical | ROB 895 | Oxypharma | ||
| Pre-clinical | Tetracycline | non-antibacterial | Paratek | |
| Pre-clinical | PXS2076 | Pharmaxis | ||
| Pre-clinical | PXS25 / PXS64 | Pharmaxis | ||
| Pre-clinical | Q-Cells | Q Therapeutics | ||
| Pre-clinical | QR-442 | Quigley | ||
| Pre-clinical | Aequorin | Quincy Bioscience | ||
| Pre-clinical | Timcodar | Recovexx | ||
| Pre-clinical | RheoSwitch Therapeutic System + TriGrid Delivery System | Rh eoGene, Ichor Medical Systems | ||
| Pre-clinical | R348 | Rigel | ||
| Pre-clinical | Gemfibrozil | Lopid | Rush University | |
| Pre-clinical | IL-1ra gene therapy | San Raffaele Scientific Institute, Mil an | ||
| Pre-clinical | CRA-028129 | cathepsin S inhibitor | Schering | |
| Pre-clinical | DZ2002 | Shanghai Institute of Materia Medica | ||
| Pre-clinical | CYLA | calpain inhibitor | SUNY Downstate Medical Center | |
| Pre-clinical | STA-5326 | Synta Pharmaceuticals | ||
| Pre-clinical | Syntonix Transceptor/SynFusion | inhaled interferon-beta:Fc | Syntonix/Serono | |
| Pre-clinical | ONO-2506 | arundic acid | Takizawa et al | |
| Pre-clinical | Oral Copaxone | Teva | ||
| Pre-clinical | Glucosamine | Thomas Jefferson University | ||
| Pre-clinical | ShK | L5 | UC Irvine | |
| Pre-clinical | Estrogen receptor alpha | ERalpha ligand | UCLA | |
| Pre-clinical | LF 15-0195 | Universite Paul Sabatier, France | ||
| Pre-clinical | 15d-PGJ | University of Arkansas | ||
| Pre-clinical | PLP-BPI | University of Kansas | ||
| Pre-clinical | MTA | methylthioadenosine | University of Navarra – Spain | |
| Pre-clinical | CT301 | University of Western Ontario | ||
| Pre-clinical | VX15 | Vaccinex and Teva | ||
| Pre-clinical | Symadex | imidazoacridinone | Xanthus | |
| Pre-clinical | Dilantin | phenytoin | Yale University | |
| Pre-clinical | Vasoactive Intestinal Peptide | VIP | ||
| Pre-clinical | CHR-1103 | Chromos | ||
| Pre-clinical | Ciliary neurotrophic factor | CNTF | ||
| Pre-clinical | MCT-175 | MultiCell | ||
| Pre-clinical | Arvanil | synthetic capsaicin-anandamide hybrid | ||
| Phase III | Revimmune | high-dose cyclophosphamide or cytoxan | Accentia Biopharmaceuticals | |
| Phase III | BG12 | Biogen | ||
| Phase III | Interferon beta 1a – PEGylated | bi-weekly or monthly injection | Biogen Idec | |
| Phase III | MBP8298 | Dirucotide | BioMS | |
| Phase III | Cannabinoids – oral | PPMS | Clinical Neurology Research Group – Plymouth | |
| Phase III | Campath | alemtuzumab | Genzyme | |
| Phase III | Progestin and Estradiol | Hospices Civils de Lyon | ||
| Phase III | MN-166 | ibudilast and Ketas | Medicinova | |
| Phase III | Mylinax | oral cladribine | Merck Serono | |
| Phase III | Minocycline | MS Society of Canada, MS Scientific Research Foundation | ||
| Phase III | FTY720 | fingolimod | Novartis | |
| Phase III | Trimesta | oral | Pipex Pharmaceuticals | |
| Phase III | Teriflunomide | HMR 1726 | Sanofi-Aventis | |
| Phase III | T-Cell Vaccination | TCV-01-002 | Sheba Medical Center | |
| Phase III | Laquinimod | ABR-215062 | Teva | |
| Phase III | Mycophenolate mofetil | Cellcept | with Avonex | |
| Phase III | Stem cells – autologous hematopoietic | ASTIMS trial | ||
| Phase II | AB1010 | Kinavet or Masitinib | AB Science | |
| Phase II | ATL/TV 1102 | Antisense Therapeutics / Teva | ||
| Phase II | ATX-MS1467 | Apitope Technology / Merck Serono | ||
| Phase II | Flupirtine | Bayer / Schering | ||
| Phase II | BHT-3009-01 | DNA vaccine | Bayhill Therapeutics | |
| Phase II | ESP | an analogue of a metabolite of azathioprine | Biomolecular Pharma / Mount Allison University | |
| Phase II | Chaperonin 10 | XToll and Cpn10 | C-Bio | |
| Phase II | Pixantrone | BBR 2778 | Cell Therapeutics | |
| Phase II | EGCg | Epigallocatechin-Gallate | Charite University, Berlin | |
| Phase II | Enkorten | FAR404 | Farmacija | |
| Phase II | GEM-SP | SPMS | Gemacbio | |
| Phase II | Ofatumumab | HuMax-CD20 | Genmab | |
| Phase II | Lamotrigine | Lamictal | Glaxosmithkline | |
| Phase II | Firategrast | SB-683699 and T-0047 | Glaxosmithkline / Tanabe | |
| Phase II | Autologous hematopoietic stem cell transplantation | HALT MS and Northwestern University | ||
| Phase II | Alferon N Injection | Hemispherx Biopharma | ||
| Phase II | LymphoStat-B | belimumab | Human Genome Sciences, Glaxosmithkline | |
| Phase II | RG2077 | CTLA4-IgG4m | Immune Tolerance Network and Repligen | |
| Phase II | Zocor | simvastatin | Merck Serono | |
| Phase II | Atacicept | TACI-Ig | Merck Serono and ZymoGenetics | |
| Phase II | Pravastatin | Nantes University Hospital – France | ||
| Phase II | Omega-3 fatty acid | Norway | ||
| Phase II | Kynurenine | Tranilast, Rizoben, 3,4-DAA | Nuon Therapeutics | |
| Phase II | RPI-78M | Nutra Pharma / ReceptoPharm | ||
| Phase II | Tovaxin | Opexa | ||
| Phase II | Lipitor | atorvastatin | Pfizer | |
| Phase II | Daclizumab | Zenapax | Protein Design Labs, Biogen-Idec | |
| Phase II | Ocrelizumab | R1594 | Roche/Genentech/Biogen | |
| Phase II | MBP8298 | BioMS | RRMS trial | |
| Phase II | Estroprogestins | with IFN beta 1a | S. Andrea Hospital | |
| Phase II | HP184 | nerispirdine | Sanofi-Aventis | |
| Phase II | Vitamin D3 | with calcium | St. Michael’s Hospital – Toronto | |
| Phase II | Erythropoietin | EPO | Stem Cell Therapeutics | |
| Phase II | Lymphocytapheresis, azathioprine & prednisone | SPMS | U of Chicago | |
| Phase II | CDP323 | UCB / Biogen | ||
| Phase II | Testosterone | UCLA | ||
| Phase II | Riluzole | with Avonex | UCSF | |
| Phase II | Hookworm | WIRMS – Worms for Immune Regulation in MS | UK | |
| Phase II | Fluoxetine | Prozac | University Medical Center Groningen | |
| Phase II | Mesenchymal Stem Cells | University of Cambridge and Hadassah Medical Organization | ||
| Phase II | Stem cell transplant from donor | not autologous | University of Louisville | |
| Phase II | Interferon alpha | oral | University of Texas-Houston | |
| Phase II | Treosulfan | SPMS | University of Wuerzburg, Germany | |
| Phase II | Minocycline | |||
| Phase II | Low-dose naltrexone | LDN | ||
| Phase II | Bacille Calmette-Guèrin | BCG Vaccine | ||
| Phase II | Doxycycline | with Avonex | ||
| Phase II | Methotrexate – intrathecal | |||
| Phase I | RTL1000 | Artielle ImmunoTherapeutics | ||
| Phase I | AZD5904 | AstraZeneca | ||
| Phase I | BaroFeron | BaroFold | ||
| Phase I | BCX-4208 | DADMe-Immunicillin-H or R3421 | BioCryst and Roche | |
| Phase I | BGC20-0134 | BTG | ||
| Phase I | CCX915 | CCR2 antagonist | ChemoCentryx | |
| Phase I | Mesenchymal stem cell transplantation | autologous | Cleveland Clinic | |
| Phase I | CS-0777 | Daiichi-Sankyo | ||
| Phase I | TBC-4746 | Encysive Pharmaceuticals / Pfizer | ||
| Phase I | Valomaciclovir | EPB-348 | Epiphany Biosciences | |
| Phase I | Far Infrared Irradiation | GAAD Medical Research Institute, Canada | ||
| Phase I | GRC 4039 | Glenmark Pharmaceuticals | ||
| Phase I | INCB8696 | Incyte | ||
| Phase I | TK54 | LTKfarma | ||
| Phase I | MM-093 | Recombinant Human Alpha-Fetoprotein | Merrimack | |
| Phase I | MLN0415 | Millenium / Sanofi-Aventis | ||
| Phase I | NI-0401 | NovImmune | ||
| Phase I | ONO-4641 | oral S1P receptor agonist | Ono Pharmaceutical | |
| Phase I | Lipoic acid | Oregon Health and Science University | ||
| Phase I | Low Fat Diet | Oregon Health and Science University | ||
| Phase I | Amiloride | Oxford University | ||
| Phase I | Cannabinor | Pharmos | ||
| Phase I | R1295 | Roche | ||
| Phase I | R3477 | Roche / Actelion | ||
| Phase I | Helminth-induced immunomodulation therapy | HINT | U of Wisconsin | |
| Phase I | Extracorporeal photochemotherapy | University of Milano-Bicocca | ||
| Phase I | Linoleic Acid | omega-6 | University of Rochester | |
| Phase I | SC12267 | 4SC AG | ||
| Phase I | Sildenafil Citrate | Viagra | ||
| Phase I | PI-2301 | Peptimmune | ||
| Off-label | Mycophenolate mofetil | Cellcept | ||
| Off-label | Cyclophosphamide | Cytoxan | ||
| Off-label | Azathioprine | Imuran | ||
| Off-label | Plasma exchange | plasmapheresis | ||
| Off-label | Intravenous Immune Globulin | IVIg | ||
| Off-label | Low-Dose Naltrexone | LDN | ||
| Off-label | Antibiotics: Doxycycline, Amoxicillin, Rifampin, Metronidazole — OR — Doxycycline, Roxithromycin, Metronidazole — OR — Rifampin, Azithromycin, Flagyl | |||
| Off-label | Methotrexate | |||
| Approved | Betaseron / Extavia | subcutaneous interferon beta 1b | Bayer / Novartis | |
| Approved | Avonex | intramuscular interferon beta 1a | Biogen Idec | |
| Approved | Tysabri | natalizumab | Biogen Idec / Elan | |
| Approved | Rebif | new formulation: fetal bovine serum-free/human serum albumin-free | Merck Serono | |
| Approved | Novantrone | mitoxantrone | Merck Serono / OSI | |
| Approved | Copaxone | glatiramir acetate | Teva | |
